Drug intelligence / Profile preview

KAdermin

Development stage
Unknown
Lead developer
Pavia Farmaceutici
Administration
Topical
01

Overview

KAdermin is a topical wound-healing medical device available as a powder spray or cream, designed to facilitate the healing of various skin lesions. It features the patented SCX/SILVERSIL CLOREX complex, which combines silicon dioxide functionalized with silver ions and chlorhexidine to provide a broad-spectrum antimicrobial barrier against wound-colonizing pathogens. The formulation also includes kaolin, which acts as an absorbent for wound exudate, and hyaluronic acid, which creates a protective, hydrated film that supports spontaneous tissue regeneration and re-epithelialization. KAdermin is indicated for the treatment of surgical wounds, ulcers, minor burns, abrasions, and other exuding skin lesions. Clinical research has specifically demonstrated its utility in managing pain and promoting healing at split-thickness skin graft donor sites.

Brand names
KAdermin
Other names
SCX complexSILVERSIL CLOREX complex
02

Targets

RHAMM (Hyaluronan-mediated motility receptor)CD44 (CD44 antigen)

Beyond the preview

Go deeper on KAdermin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAdermin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call